Xerox Holdings Corporation


XRX

announced yesterday that it has appointed Jacques-Edouard Gueden as executive vice president and president of Europe, Middle East & Africa (EMEA) Operations. He has been on these roles on an interim basis since September-end.

During his 32 years tenure with Xerox, Gueden has served several leadership positions. Most recently, he was president of France, Belgium and Luxembourg before which he served as senior vice president of EMEA Business Operations and Marketing.

John Visentin, Xerox’s vice chairman and CEO said, “Jacques-Edouard will be responsible for Xerox’s go-to-market teams across EMEA to bring Xerox’s full portfolio of products, services and software to new and existing clients and partners.”

Thus,the appointment seems to be a part of Xerox’s aggressive product development program for new high-growth markets, a counter strategy that the company has been using to handle declining sales due to decreased demand for paper-related systems and products.

Xerox recently reported its fourth-quarter 2020 results in which adjusted earnings per share of 58 cents missed the Zacks Consensus Estimate by 3.3% and declined 56.4% year over year. Total revenues of $1.93 billion surpassed the consensus mark by 1.9% but declined 21% year over year. The coronavirus pandemic had a significant negative impact on the company’s quarterly results.

Xerox’s shares have gained 47.1% over the past six months compared with 41.7% rally of the

industry

it belongs to.

Zacks Rank and Stocks to Consider

Xerox currently carries a Zacks Rank #4 (Sell).

Some better-ranked service stocks are

SailPoint Technologies


SAIL

,

NV5 Global


NVEE

and

TeleTech Holdings


TTEC

, each carrying a Zacks Rank #2 (Buy). You can see


the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here


.

The long-term expected earnings per share (three to five years) growth rate for SailPoint, NV5 Global and TeleTech is 15%, 18% and 19.4%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

To read this article on Zacks.com click here.